25412-66-2

Usage

Uses

Used in Organic Synthesis:
3-Methoxy-benzamidine is used as a reagent in organic synthesis for its capacity to facilitate the formation of complex organic molecules, contributing to the development of pharmaceuticals and other fine chemicals.
Used in Pharmaceutical Production:
As a precursor, 3-Methoxy-benzamidine is utilized in the production of certain pharmaceuticals, playing a crucial role in the synthesis of active ingredients that address various health conditions.
Used in Biochemical Research:
3-Methoxy-benzamidine is employed as a research tool to study the role of proteases in biological processes, given its ability to inhibit these enzymes' activity, which aids in understanding their function and implications in disease mechanisms.
Used in Drug Development:
In the development of new drug candidates, 3-Methoxy-benzamidine serves as a key component targeting protease activity, potentially leading to treatments for diseases associated with abnormal protease function.
Used in Medical Diagnostics:
3-Methoxy-benzamidine has potential applications in the field of medical diagnostics as a substrate for detecting protease activity in biological samples, which can be instrumental in diagnosing and monitoring diseases related to proteases.

InChI:InChI=1/C8H10N2O/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5H,1H3,(H3,9,10)

Upstream product

• 73647-50-4 N'-hydroxy-3-methoxybenzenecarboximidamide 
• 1527-89-5 3-methoxybenzonitrile 

Downstream Products

• 1001755-35-6 [2-(3-Methoxy-phenyl)-3H-imidazol-4-yl]-methanol 
• 582306-99-8 4-amino-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidine-5-carbonitrile 
• 1613637-80-1 2,4-bis(3-methoxyphenyl)-1,3,5-triazine 
• 1898-74-4 2,4-diphenyl-1,3,5-triazine 
• 1613637-87-8 2-(3-methoxyphenyl)-4-phenyl-1,3,5-triazine 
• 1416892-55-1 C₂₃H₂₆N₄O₄ 
• 1416892-54-0 C₁₆H₁₃N₃O₃ 
• 1026594-08-0 5-Chloromethyl-2-(3-methoxy-phenyl)-1H-imidazole 

Relevant academic research and scientific papers

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

INHINITORS OF GLI1 AS THERAPEUTIC AGENTS

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma- associated oncogene (Gli) expression. More particularly, this disclosure relate

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Direct Conversion of Amidoximes to Amidines via Transfer Hydrogenation

Amidoximes, O-alkylamidoximes, and O-acylamidoximes are directly converted to amidines by reaction with ammonium formate and Pd/C in acetic acid.

Pyridine and pyrimidine derivatives

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment

2-Phenyl-4-(aminomethyl)imidazoles as Potential Antipsychotic Agents. Synthesis and Dopamine D2 Receptor Binding

A series of 2-phenyl-4-(aminomethyl)imidazoles were designed as conformationally restricted analogs of the dopamine D2 selective benzamide antipsychotics.The title compounds were synthesized and tested for blockade of YM-09151 binding in cloned African green monkey dopamine D2 receptor preparations.The binding affinity data thus obtained were compared against that of the benzamides and a previously described series of 2-phenyl-5-(aminomethyl)pyrroles.